A review on the taste masking of bitter APIs: Hot-melt extrusion (HME) evaluation

Drug Development and Industrial Pharmacy

Volumn 40, Issue 2, 2014, Pages 145-156

  Maniruzzaman, Mohammed ^a   Boateng, Joshua S ^a   Chowdhry, Babur Z ^a   Snowden, Martin J ^a   Douroumis, Dennis ^a  

^a UNIVERSITY OF GREENWICH   (United Kingdom)

Author keywords

Bitter APIs; Hot melt extrusion; Inter molecular interactions; Modified release; Molecular dispersion; Taste assessment; Taste masking

Indexed keywords

DRUG; LIPID; PLASTICIZER;

BITTER TASTE; CRYSTALLIZATION; DISPERSION; DRUG FORMULATION; DRUG SOLUBILITY; MOLECULAR INTERACTION; NONHUMAN; PALATABILITY; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG EVALUATION, PRECLINICAL; HOT TEMPERATURE; HUMANS; PHARMACEUTICAL PREPARATIONS; TASTE;

EID: 84892801126     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2013.804833     Document Type: Review

References (76)

1. Salunke S, Giacoiac G, Tuleua C. The STEP (Safety and Toxicity of Excipients for Paediatrics) database. Part 1-a need assessment study. Int J Pharm 2012;435:101-11.
2. Woertz K, Tissen C, Kleinebudde P, Breitkreutz J. Rational development of taste masked oral liquids guided by an electronic tongue. Int J Pharm 2010;400:114-23.
3. European Pharmacopoeia, 6th ed. (6.7). Strasbourg Cedex, France, pp. 255-256, 2800-2801; 2010.
4. Maniruzzaman M, Rana M, Boateng JS, Douroumis D. Dissolution enhancement of indomethacin and famotidine processed by hot-melt extrusion. Drug Dev Ind Pharm 2013;39:218-27.
5. Maniruzzaman M, Boateng JS, Snowden MJ, Douroumis D. A review of hot-melt extrusion: process technology to pharmaceutical products. ISRN Pharm 2012;2012:436763.
6. Committee for Medicinal Products for Human Use, EMA, 2006. Reflection paper: Formulation of choice for the paediatric population, 45 pp. Available from: http://www. EMA.europa.eu/pdfs/ human/paediatrics/19481005en.pdf [last accessed 23 Sep 2012].
7. EMA, 2004. Evidence of harm from off-label or unlicensed medicines in children. Available from: http://www.emea.europa.eu/ pdfs/human/paediatrics/ 12632704en.pdf [last accessed 23 Sep 2012].
8. EMA, 2007. Commission guideline on the format and content of applications for agreement or modification of a paediatric investigation plan and requests for waivers or deferrals, and concerning the operation of the compliance check, and on criteria for assessing significant studies (Draft). Available from: http://ec.europa.eu/ enterprise/pharmaceuticals/paediatrics/docs/draft guideline pip 2007- 02.pdf [last accessed 23 Oct 2012].
9. Campbell GA, Charles JA, Roberts-Skilton K, et al. Evaluating the taste masking effectiveness of various flavors in a stable formulated paediatric suspension and solution using the Astree electronic tongue. Powder Tech 2012;224:109-23.
10. EMA, 2008. Ethical considerations for clinical trials on medicinal products conducted with the paediatric population. Available from: http://ec.europa.eu/enterprise/ pharmaceuticals/eudralex/vol-10/ ethical considerations.pdf [last accessed 23 Sep 2012].
11. Douroumis D. Practical approaches of taste masking technologies in oral solid forms. Exp Opin Drug Deliv 2007;4:417-26.
12. Douroumis D. Orally disintegrating dosage forms and taste-masking technologies. Exp Opin Drug Deliv 2011;8:665-75.
13. Davies HE, Tuleu C. Medicines for children: a matter of taste. J Pediatr 2008;153:599-604.
14. O'Donnell J, Mertl SL, Kelly WN. Propylene glycol toxicity in a pediatric patient: the dangers of diluents. J Pharm Prac 2000;13: 214-25.
15. Doty RL, Shah M, Bromley SM. Drug-induced taste disorders. Drug Safety 2008;31:199-215.
16. Strickley RG, Iwata Q, Wu S, Dahl TC. Pediatric drugs - a review of commercially available oral formulations. J Pharm Sci 2008;97: 1731-74.
17. Woertz K, Tissen C, Kleinebudde P, Breitkreutz J. A comparative study on two electronic tongues for pharmaceutical formulation development. J Pharm Biomed Anal 2011;55:272-81.
18. Woertz K, Tissen C, Kleinebudde P, Breitkreutz J. Performance qualification of an electronic tongue based on ICH guideline Q2. J Pharm Biomed Anal 2010;51:497-506.
19. Ayenew Z, Puri V, Kumar L, Bansal AK. Trends in pharmaceutical tastemasking technologies: a patent review. Recent Pat Drug Deliv Formul 2009;3:26-39.
20. Douroumis DD, Gryczke A, Schminke S. Development and evaluation of cetirizine HCl taste-masked oral disintegrating tablets. AAPS PharmSciTech 2011;12:141-51.
21. Al-Omran MF, Al-Suwayeh SA, El-Helw AM, Saleh SI. Taste masking of diclofenac sodium using microencapsulation. J Microencapsul 2002;19:45-52.
22. Shah PP, Mashru RC, Rane YM, Thakkar A. Design and optimization of mefloquine hydrochloride microparticles for bitter taste masking. AAPS PharmSciTech 2008;9:377-89.
23. Albertini B, Cavallari C, Passerini N, et al. Characterization and taste-masking evaluation of acetaminophen granules: comparison between different preparation methods in a high-shear mixer. Eur J Pharm Sci 2004;21:295-303.
24. Benoit JP, Rolland H, Thies C, VandeVelde V. Method of coating particles and coated spherical particles. US Patent 2000;6:003.
25. Bora D, Borude P, Bhise K. Taste masking by spray-drying technique. AAPS PharmSciTech 2008;9:1159-64.
26. Schiffman SS, Zervakis J, Suggs MS, et al. Effect of tricyclic antidepressants on taste responses in humans and gerbils. Pharmacol Biochem Behav 2000;65:599-609.
27. Cotterill JV, Massei G, Cowan DP, et al. Masking the taste of the conditioned taste aversion agent levamisole using an ion-exchange resin, for practical application in wildlife management. Pest ManagSci 2005;62:120-5.
28. Clapham D, Kirsanov D, Legin A, et al. Assessing taste without using humans: rat brief access aversion model and electronic tongue. Int J Pharm 2012;435:13-51.
29. Formaker BK, Stapleton JR, Roper SD, Frank ME. Responses of the rat chorda tympani nerve to glutamate-sucrose mixtures. ChemSen 2004;29:473-82.
30. Zotterman Y. Action potentials in the glossopharyngeal nerve and in the chorda tympani. Skand Arch Physiol 1935;72:73-7.
31. Scott TR, Giza BK, Yan J. Gustatory neural coding in the cortex of the alert cynomolgus macaque: the quality of bitterness. J Neurophysiol 1999;81:60-71.
32. Oakley B. Taste responses of human chorda tympani nerve. Chem Senses 1985;10:469-81.
33. Anand V, Kataria M, Kukkar V, et al. The latest trends in the taste assessment of pharmaceuticals. Drug Discov Today 2007;12: 257-65.
34. Schiffman SS, Zervakis J, Suggs MS, et al. Effect of medications on taste: example of amitriptyline HCl. Physiol Behav 1999;66:183-91.
35. Glibertson TA, Damak S, Margolskee RF. The molecular physiology of taste transduction. Curr Opinion Neurobiol 2000;10:519-27.
36. Ruiz-Avila L, Ming D, Margolskee RF. An in vitro assay useful to determine the potency of several bitter compounds. Chem Senses 2000;25:361-8.
37. Toko K. Taste sensor. SensActua B 2000;64:205-15.
38. Ishizaka T, Miyanaga Y, Mukai J, et al. Bitterness evaluation of medicines for paediatric use by a taste sensor. Chem Pharm Bull 2004;52:943-8.
39. Funasaki N, Uratsuji I, Okuno T, et al. Masking mechanisms of bitter taste of drugs studied with ion selective electrodes. Chem Pharm Bull 2006;54:1155-61.
40. Intellegent Sensing Technology, Inc, Japan. Available from: http:// www.insent.co.jp [last accessed Sep 2012].
41. Mifsud JC, Lucas Q. Alpha M.O.S. Apparatus and method for characterizing liquids. 2003: US Patent 6,290,838.
42. Woertz K, Tissen C, Kleinebudde P, Breitkreutz J. Performance qualification of an electronic tongue based on ICH guideline Q2. J Pharm Biomed Anal 2010;51:497-506.
43. Woertz K, Tissen C, Kleinebudde P, Breitkreutz J. A comparative study on two electronic tongues for pharmaceutical formulation development. J Pharm Biomed Anal 2011;55:272-81.
44. Makoto T, Masaaki H. A report on bitterness evaluation of APIs and excipients by Taste Sensing System TS-5000Z. Intelligent Sensor Technology, Inc. (INSENT, Japan). Jan 2012.
45. Petereit HU, Meier C, Gryczke A. Melt extrusion consisting of salts of active ingredients. 2003 WO03/072083 A2.
46. Douroumis D, Bonnefille M, Aranyos A. Taste masking using hot melt extrusion. In: Douroumis, ed. Pharmaceutical applications of hot-melt extrusion. Chichester, UK: Wiley and Sons; 2012.
47. Gryckze A. Innovative formulations by melt extrusion with EUDRAGIT polymers. Darmstadt: ROHM GmbH & Co. KG; 2006.
48. Petereit HU, Meier C, Gryczke A. Method for producing an immediately decomposing oral form of administration which releases active ingredients. US 2006/0051412 A1.
49. Gryczke A, Schminke S, Maniruzzaman M, et al. Development and evaluation of orally disintegrating tablets (ODTs) containing ibuprofen granules prepared by hot melt extrusion. Coll Surf (B) Biointerfaces 2011;86:275-84.
50. De Brabander C, Van Den Mooter G, Vervaet C, Remon JP. Characterization of ibuprofen as a non-traditional plasticizer of ethyl cellulose. J Pharm Sci 2002;91:1678-85.
51. Maniruzzaman M, Boateng J, Douroumis D. Taste masking of bitter APIs by using hot melt extrusion (HME). AAPS J 2011;13: T3273.
52. Maniruzzaman M, Boateng JS, Bonnefille M, et al. Taste masking of paracetamol by hot-melt extrusion: an in vitro and in vivo evaluation. Eur J Pharm Biopharm 2012;80:433-42.
53. Maniruzzaman M, Pang J, Mendham A, et al. Intermolecular interactions of solid dispersions processed by hot melt extrusion. AAPS J 2012;14:W5324.
54. Maniruzzaman M, Morgan D, Mendham A, et al. Drug-polymer intermolecular interactions in hot-melt extruded solid dispersions. Int J Pham 2013;443:199-208.
55. Barthelemy P, Laforêt JP, Farah N, Joachim J. Compritol 888 ATO: an innovative hot-melt coating agent for prolonged-release drug formulations. Eur J Pharm Biopharm 1999;47:87-90.
56. Faham A, Prinderre P, Farah N, et al. Hot-melt coating technology. I. Influence of Compritol 888 Ato and granule size on theophylline release. Drug Dev Ind Pharm 2000;26:167-76.
57. Suzuki H, Onishi H, Takahashi Y, et al. Development of oral acetaminophen chewable tablets with inhibited bitter taste. Int J Pharm 2003;251:123-32.
58. Breitkreutz J, Bornhoft M, Woll F, Kleinebudde P. Pediatric drug formulations of sodium benzoate: I. Coated granules with a hydrophilic binder. Eur J Pharm Biopharm 2003;56:247-53.
59. Breitkreutz J, El-Saleh F, Kiera C, et al. Pediatric drug formulations of sodium benzoate: II. Coated granules with a lipophilic binder. Eur J Pharm Biopharm 2003;56:255-60.
60. Krause J, Thommes M, Breitkreutz J. Immediate release pellets with lipid binders obtained by solvent-free cold extrusion. Eur J Pharm Biopharm 2009;71:138-44.
61. Michalk A, Kanikanti VR, Hamann HJ, Kleinebudde P. Controlled release of active as a consequence of the die diameter in solid lipid extrusion. J Control Release 2008;132:35-41.
62. Witzleb R, Kanikanti VR, Hamann HJ, Kleinebudde P. Solid lipid extrusion with small die diameters-electrostatic charging, taste masking and continuous production. Eur J Pharm Biopharm 2011; 77:170-7.
63. Kalivodaa A, Fischbacha M, Kleinebuddeb P. Application of mixtures of polymeric carriers for dissolution enhancement of fenofibrate using hot-melt extrusion. Int J Pharm 2012;429: 58-68.
64. Boateng JS, Stevens HNE, Eccleston GM, et al. Development and mechanical characterization of solventcast polymeric films as potential drug delivery systems to mucosal surfaces. Drug Dev Ind Pharm 2009;35:986-96.
65. Steuernagel CR. Latex emulsions for controlled drug delivery. In: McGinity JW, ed. Aqueous polymeric coatings for pharmaceutical dosage forms, Vol. 79. New York: Marcel Dekker Inc.; 1997.
66. Barnhart S. Thin film oral dosage forms. In: Rathbone MJ, Hadgraft J, Roberts MS, Lane ME, eds. Modified-release drug delivery technology (drugs and the pharmaceutical sciences). New York, USA: Informa Healthcare; 2008:209-16.
67. International Conference on Harmonization. ICH topic Q3C (R3) Impurities: residual solvents, 2009. Available from: http:// www.emea.europa.eu/pdfs/human/ ich/028395en.pdf [last accessed Oct 2012].
68. Morales JO, McConville JT. Manufacture and characterization of muco-adhesive buccal films. Eur J Pharm Biopharm 2011;77: 187-99.
69. Tumuluri VS, Kemper MS, Lewis IR, et al. Off-line and on-line measurements of drug-loaded hot-melt extruded films using raman spectroscopy. Int J Pharm 2008;357:77-84.
70. Mishra R, Amin A. Formulation development of taste-masked rapidly dissolving films of cetirizine hydrochloride. Pharm Tech 2009;33:48-56.
71. Mididoddi PK, Repka MA. Characterization of hot-melt extruded drug delivery systems for onychomycosis. Eur J Pharm Biopharm 2007;66:95-105.
72. Prodduturi S, Manek R, Kolling W, et al. Solid-state stability and characterization of hot-melt extruded poly(ethylene oxide) films. J Pharm Sci 2005;94:2232-45.
73. Repka M, Gerding T, Repka S, McGinity J. Influence of plasticizers and drugs on the physical-mechanical properties of hydroxypropylcellulose films prepared by hot melt extrusion. Drug Dev Ind Pharm 1999;25:625-33.
74. Cilurzo F, Cupone IE, Minghetti P, et al. Fast dissolving films made of maltodextrins. Eur J Pharm Biopharm 2008;70:895-900.
75. Repka MA, Prodduturi S, Stodghill SP. Production and characterization of hot-melt extruded films containing clotrimazole. Drug Dev Ind Pharm 2003;29:757-65.
76. Prodduturi S, Manek RV, Kolling B, et al. Water vapor sorption isotherms of hot-melt extruded hydroxypropyl cellulose films: effect on physico-mechanical properties, release characteristics and stability. J Pharm Sci 2004;93:3047-56